Stem Cell Therapeutics Corp.
TSX VENTURE : SSS

Stem Cell Therapeutics Corp.

July 07, 2008 09:00 ET

Stem Cell Therapeutics Announces Issuance of Keystone Prolactin Patents

SCT is granted intellectual property protection in United States and Australia covering use of Prolactin to treat neurodegenerative diseases

CALGARY, ALBERTA--(Marketwire - July 7, 2008) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) is pleased to announce the Company has been issued two corresponding patents to strengthen its intellectual property landscape through United States and Australia.

The U.S. patent, numbered 7,393,830 and entitled "Prolactin induced increase in neural stem cell numbers" was issued July 1, 2008. The Australian patent, numbered 2002325711 and entitled "Prolactin induced increase in neural stem cell numbers and therapeutical use thereof" was issued January 10, 2008. These are the first patents to issue in this patent family.

Dr. Alan Moore, President and CEO of SCT commented as follows:

"What is particularly important about these patents is that they cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad base of protection. We have the exclusive right to the use of prolactin for treating neurodegenerative diseases and therefore have a strong foundation to develop many possible products using prolactin, either as a single therapeutic or in combination with other neurogenic agents. For example, this intellectual property supports programs currently under development using prolactin alone or with anti-inflammatories to treat multiple sclerosis and using a combination of prolactin and EPO to treat other neurodegenerative diseases."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury and multiple sclerosis. SCT is currently recruiting patients for the multi-centre, double-blind, placebo-controlled REGENESIS Phase IIb acute stroke study for its lead program, NTx™-265, with primary endpoints of efficacy. Patient enrolment is expected to be complete by the end of 2008 with top-line efficacy data expected to be released before the end of the first quarter of 2009.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information